Our Strategy

Developing Regulatory Intelligence & Representing the Human Microbiome Supply Chain

Main Representative Organization

The PRI wishes to be the main representative organization interrogated by the competent authorities regarding the future regulatory framework for MMPs (including LBPs) and to become the N°1 network for the European microbiome pharmaceutical supply chain, federating fundamental actors from the industry, such as stakeholders involved in the development, investment, production and commercialization of MMPs.

Future of Medicine

The Human Microbiome represents a paradigm shift in how human medicines will be developed – as innovation and industry often outpace regulation, our mission is to facilitate the conversation between European regulators and microbiome therapeutics developers and their partners so that Microbiotic Medicinal Products become a therapeutic reality.

Unique Collaborative Approach

A Unique Collaborative Approach – as a neutral, financially-independent non-profit association, the PRI applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members.

Our Membership Packages

Partnering Membership

Active Support

Active Support

Active support in identifying potential partnerships

Annual Event

Annual Event

Invitation to annual exclusive Member Event for Partnering + Innovation Showcase

Task Groups

Task Groups

PRI Task Groups* (Non-regulatory topics only) 

Digital Promotion

Digital Promotion

Promotion on PRI website (logo, blog articles, newsletters) & social media (LinkedIn, Twitter)

Discounted Rates

Discounted Rates

Discounted Rate (up to 20%) to attend + advantages for sponsoring at the annual Pharmabiotics Conference & Partnering event

Regulatory Membership

*Includes all advantages of Partnering Membership

On-site Workshops

On-site Workshops

Customized on-site workshops with our regulatory affairs experts to de-risk and accelerate your product development

Unique Expertise

Unique Expertise

PRI internal guidelines & previous scientific advice intelligence

Task Groups

Task Groups

All PRI Task Groups (regulatory & technical). These ad-hoc working groups focus on the most pressing questions facing the industry – eg. ‘Clinical Studies’, ‘Analytics’, ‘Safety’, ‘Inactivated Cells’…

Future Outlook

Future Outlook

Foresight of future regulatory challenges

Regulatory Strategy

Regulatory Strategy

PRI regulatory strategy (EMA Scientific Advice Request dossier results) – the ‘overview effect’

Keeping Up

Keeping Up

Current European regulatory intelligence updates Eg. European Pharmacopeia or CAMD Medical Device Status

Valuable Insight

Valuable Insight

Actively provide you with a unique understanding of the authorities’ mindset/approach to microbiome-based products (LBPs/MMPs)

Fee Structure

Scroll to view our Regulatory Membership Fees Structure

Membership Fees Structure

Regulatory Membership:

Annual Company/Group Turnover => Annual Membership Dues

Partnering Membership:

Annual Turnover

Organization 

Membership Dues

Membership Dues

0 to €3 million

0 to €10 million     

 €10 million

€ 3,000

€ 7,000

€ 10,000

Partnering Member (Industry)

Associate Member (Research/Academia)

€ 1,500/ year

Free of Charge

Membership Fees Structure

Annual Company/Group Turnover => Annual Membership Dues

Regulatory Membership:

Annual Turnover

Membership Dues

0 to €3 M

0 to €10 M     

> €10 M 

€ 3,000

€ 7,000

€ 10,000

Partnering Membership:

Organization

Membership Dues

Partnering Member 

Associate Member 

€ 1,500/ year

Free of Charge